ucp2 Antibody

What is UCP2 and why is it significant in research?

UCP2 (Uncoupling Protein 2) is a mitochondrial inner membrane protein that belongs to the family of mitochondrial anion carrier proteins. It plays crucial roles in regulating mitochondrial ROS production, energy metabolism, and various cellular processes. UCP2 has gained significant research interest because of its involvement in regulating erythropoiesis (red blood cell formation), with evidence suggesting that inhibition of UCP2 function may contribute to anemia development . Additionally, UCP2 has emerged as a potential prognostic marker in cancer research, particularly in breast cancer, where its expression correlates with better clinical outcomes . The multifaceted roles of UCP2 in cell proliferation, immune function, and disease pathogenesis make it an important target for antibody-based research applications.

What are the typical specifications of UCP2 antibodies used in research?

UCP2 antibodies for research applications typically have the following specifications:

Research-grade UCP2 antibodies are typically validated for specificity against other UCP family members (UCP1, UCP3, UCP4) to ensure selective detection of UCP2 .

What is the expected molecular weight of UCP2 in different detection systems?

UCP2 may appear at different molecular weights depending on the detection system used:

These variations in detected molecular weight highlight the importance of using appropriate positive controls and standardized protocols when analyzing UCP2 expression. The differences may result from post-translational modifications, sample preparation methods, or the specific characteristics of different detection platforms .

How should UCP2 antibodies be optimized for Western blot applications?

Optimization of UCP2 antibodies for Western blot requires careful consideration of several parameters:

• Antibody concentration: Typically 1 μg/mL of primary antibody provides optimal results for UCP2 detection in Western blot applications using the Goat Anti-Human/Mouse UCP2 Antigen Affinity-purified Polyclonal Antibody .

• Buffer conditions: Use appropriate immunoblot buffer groups (e.g., Immunoblot Buffer Group 4 as mentioned in the search results) for optimal detection .

• Reducing conditions: UCP2 is typically detected under reducing conditions, which helps maintain consistent protein conformation and migration patterns .

• Detection system: Use compatible secondary antibodies such as HRP-conjugated Anti-Goat IgG for visualization .

• Controls: Include recombinant UCP2 as a positive control and related UCP family members (UCP1, UCP3, UCP4) to confirm specificity .

• Sample preparation: Proper tissue or cell lysate preparation is critical; mouse brown adipose tissue has been successfully used as a source of endogenous UCP2 protein .

Following these optimization steps will help ensure specific and reproducible detection of UCP2 protein in experimental samples.

What protocols are effective for UCP2 detection in immunohistochemistry (IHC)?

Effective IHC protocols for UCP2 detection, as demonstrated in breast cancer tissue analysis, include:

This methodological approach enables quantitative assessment of UCP2 expression patterns that can be correlated with clinical parameters, functional data, or other experimental variables.

How can researchers differentiate between UCP2 and other UCP family members in their experiments?

Differentiating between UCP2 and other UCP family members (UCP1, UCP3, UCP4) requires strategic experimental design:

• Antibody validation: Use antibodies validated against multiple UCP family members. For example, search result describes validation of a UCP2 antibody against recombinant human UCP1, UCP2, UCP3, and UCP4 proteins to confirm specificity.

• Molecular weight discrimination: While UCP family members have similar molecular weights, they can often be distinguished by precise molecular weight determination (UCP2 typically detected at ~33 kDa under standard Western blot conditions) .

• Expression pattern analysis: Different UCP proteins have distinct tissue expression patterns that can aid discrimination:

  • UCP1 is primarily expressed in brown adipose tissue and associated with thermogenesis

  • UCP2 has a broader tissue distribution

  • UCP3 is predominantly expressed in skeletal muscle

• Genetic approaches: Using tissues from UCP2 knockout models provides definitive negative controls for UCP2-specific signals .

• Peptide competition assays: Pre-incubation of antibodies with specific blocking peptides can confirm signal specificity.

Implementing these approaches systematically helps ensure that experimental observations are accurately attributed to UCP2 rather than other family members.

How does UCP2 regulate cellular ROS distribution and what are the methodological approaches to study this?

UCP2 plays a critical role in regulating the distribution of reactive oxygen species (ROS) between mitochondrial and cytosolic compartments. This function can be studied through several methodological approaches:

These approaches collectively demonstrate that UCP2 maintains a balance between mitochondrial and cytosolic ROS, with its deficiency shifting ROS toward mitochondrial compartments while decreasing cytosolic ROS levels .

What is the relationship between UCP2 and cell proliferation in the MAPK/ERK pathway?

UCP2 influences cell proliferation through modulation of the MAPK/ERK pathway in a ROS-dependent manner:

• Pathway relationship: UCP2 deficiency results in:

  • Decreased cell proliferation, particularly at the erythropoietin-dependent phase of erythropoiesis

  • Reduction in the phosphorylated (active) form of ERK, which serves as a ROS-dependent cytosolic regulator of cell proliferation

• Mechanistic connection: The link between UCP2 and MAPK/ERK appears to be mediated through ROS regulation:

  • UCP2 deficiency alters ROS distribution between cellular compartments

  • This altered ROS distribution affects the activation state of the MAPK/ERK pathway

  • Decreased cytosolic ROS in UCP2-deficient cells correlates with reduced ERK phosphorylation

• Experimental validation: The relationship was confirmed through intervention studies:

  • Restoration of cytosolic oxidative state using the pro-oxidant Paraquat reversed the proliferation defect in UCP2-deficient cells

  • This intervention restored cell proliferation without restoring UCP2 expression, confirming that the effect was mediated through ROS modulation

This mechanistic relationship has significant implications for understanding how UCP2 may influence proliferative disorders, including cancer and hematological conditions.

How is UCP2 expression associated with cancer prognosis and what methodological approaches confirm this relationship?

UCP2 expression shows significant associations with cancer prognosis, particularly in breast cancer, as demonstrated through multiple methodological approaches:

• Transcriptomic analysis: Analysis of UCP2 mRNA expression using public databases (TCGA-BRCA cohort, Kaplan-Meier plotter) demonstrated that high UCP2 expression correlates with better clinical outcomes .

• Immunohistochemical validation: In a cohort of 107 breast cancer patients:

  • 62.6% (67/107) showed high UCP2 expression by IHC

  • High expression correlated with better relapse-free survival (RFS)

  • Cox regression analysis confirmed UCP2 as an independent prognostic factor

• Synergistic marker evaluation: Combined assessment of UCP1 and UCP2 expression showed enhanced prognostic value compared to either marker alone .

• Molecular subtype analysis: UCP2 prognostic value varied across breast cancer molecular subtypes, with particularly strong association in Basal-like breast cancers, which are more responsive to immunotherapy .

• Mechanistic pathway analysis: Gene Set Enrichment Analysis (GSEA) revealed associations between UCP2 expression and immune-related pathways:

  • B cell receptor signaling

  • T cell receptor signaling

  • Leukocyte transendothelial migration

These methodological approaches collectively establish UCP2 as a positive prognostic marker in breast cancer, potentially through mechanisms involving immune modulation.

What immune cell populations correlate with UCP2 expression in tumors and how can this be analyzed?

UCP2 expression in tumors shows significant correlations with various immune cell populations, which can be analyzed through computational and experimental approaches:

These correlations can be analyzed through:

• Computational deconvolution: Tools like TIMER (Tumor Immune Estimation Resource) and CIBERSORT algorithm can calculate tumor purity and immune cell infiltration from transcriptomic data .

• Correlation analysis: Spearman's correlation can assess relationships between UCP2 expression and immune cell populations .

• Pathway enrichment analysis: Gene Set Enrichment Analysis (GSEA) with KEGG and GO annotations can identify enriched immune-related pathways associated with UCP2 expression .

• Multi-parameter immunohistochemistry: Experimental validation of computational findings through multiplex staining of tumor tissues for UCP2 and immune cell markers.

The positive correlation of UCP2 with CD8+ T cells and M1 macrophages, coupled with negative correlation with M2 macrophages, suggests that UCP2 may influence anti-tumor immunity, potentially making it relevant for immunotherapy approaches .

How can researchers investigate the role of UCP2 in erythropoiesis and anemia development?

Investigating UCP2's role in erythropoiesis and anemia development requires specialized methodological approaches:

• Genetic models: Utilize UCP2 knockout mice to study the impact of UCP2 deficiency on erythroid development .

• Flow cytometry analysis: Implement erythroid differentiation assays with markers to identify distinct developmental stages:

  • R1: Early erythroid progenitors

  • R2: Proerythroblasts

  • R3: Basophilic erythroblasts

  • R4: Late basophilic and polychromatophilic erythroblasts

  • R5: Orthochromatic erythroblasts

• In vitro differentiation assays: Culture bone marrow cells with erythropoietin to assess erythroid differentiation capacity .

• ROS modulation experiments: Manipulate cellular redox state to determine the relationship between UCP2, ROS, and erythropoiesis:

  • TBAP (superoxide dismutase mimetic) treatment delays cell maturation at the proerythroblast stage

  • Paraquat (pro-oxidant) increases cells in the proerythroblast population, with stronger effects in UCP2-deficient cells

• MAPK/ERK pathway analysis: Assess ERK phosphorylation status in erythroid progenitors as a readout of proliferative capacity .

• Protein oxidation assays: Compare oxidation levels in mitochondrial versus total cellular proteins to understand compartmental ROS distribution .

These approaches have revealed that UCP2 regulates erythropoiesis by modulating ROS distribution and subsequently affecting MAPK/ERK signaling, with UCP2 deficiency potentially contributing to anemia development .

What experimental considerations are important when studying UCP2 in relation to disease mutational landscapes?

When studying UCP2 in relation to disease mutational landscapes, several experimental considerations are essential:

• Cohort stratification: Divide patient cohorts based on UCP2 expression levels (high vs. low) to analyze differential mutational patterns. This approach revealed that:

  • Both UCP1-high and UCP2-high expression groups showed higher frequency of CDH1 mutations

  • UCP1-high expression group had significantly lower frequency of TP53 mutations

  • UCP2-high expression group had significantly higher frequency of PIK3CA mutations

• Statistical analysis: Apply appropriate statistical methods (e.g., chi-square test) to identify significant differences in mutation frequencies between UCP2 expression groups .

• Molecular subtyping: Consider tumor molecular subtypes when analyzing UCP2-mutation relationships, as associations may vary across subtypes .

• Functional validation: Design experiments to test whether specific mutations affect UCP2 expression or function, or whether UCP2 expression influences the phenotypic consequences of common mutations.

• Pathway integration: Analyze how mutations in specific pathways (e.g., PIK3CA in the PI3K pathway) might interact with UCP2-mediated processes such as ROS regulation or immune function .

• Thermogenesis assessment: Consider evaluating thermogenic properties of tumors in relation to UCP expression and mutational status, as UCP1 expression correlates with thermogenesis in breast cancer (although UCP2 did not show significant correlation with thermogenesis) .

These considerations enable more comprehensive understanding of how UCP2 expression interacts with the broader genomic landscape in diseases like cancer.

What controls should be implemented when working with UCP2 antibodies in research?

Implementing appropriate controls is critical for reliable UCP2 antibody-based research:

• Positive tissue controls: Use tissues with known UCP2 expression:

  • Mouse brown adipose tissue has been validated as a reliable positive control for UCP2 expression

  • Consider tissue-specific expression levels when selecting appropriate positive controls

• Specificity controls:

  • Include recombinant UCP2 protein as a positive control

  • Test against related UCP family members (UCP1, UCP3, UCP4) to confirm specificity

  • Consider peptide competition assays to verify epitope specificity

• Genetic controls:

  • When available, use samples from UCP2 knockout models as definitive negative controls

  • Consider siRNA or shRNA knockdown cells as alternative negative controls

• Technical controls:

  • Include loading controls (e.g., β-actin) for normalization in Western blot applications

  • For IHC, include isotype controls and tissue sections without primary antibody

• Validation across techniques:

  • Confirm key findings using multiple detection methods (e.g., Western blot and IHC)

  • Consider orthogonal approaches such as mRNA quantification to support protein expression data

• Pharmacological validation:

  • Use modulators of UCP2 expression or function (e.g., adiponectin enhances UCP2 mRNA stability and protein synthesis)

  • Inhibitors like actinomycin D or cycloheximide can serve as controls for expression studies

Implementing these controls systematically enhances the reliability and interpretability of UCP2 antibody-based research.

How can researchers address variability in UCP2 molecular weight detection across different experimental systems?

Addressing variability in UCP2 molecular weight detection requires systematic technical approaches:

• Standardized reference samples: Include consistent positive control samples (e.g., recombinant UCP2 protein) across experiments to establish reliable reference points for molecular weight determination .

• System-specific calibration: Recognize that different detection systems may yield different apparent molecular weights:

  • Standard Western blot: ~33 kDa

  • Simple Western™: ~38 kDa

  • Calibrate expectations based on the specific system being used

• Buffer and condition optimization: Maintain consistent experimental conditions:

  • Use standardized reducing conditions for UCP2 detection

  • Employ appropriate immunoblot buffer groups (e.g., Immunoblot Buffer Group 4)

  • Document any modifications to standard protocols

• Multiple antibody validation: When possible, use multiple antibodies targeting different UCP2 epitopes to confirm detection patterns.

• Post-translational modification assessment: Consider whether variations in molecular weight might reflect biological differences in post-translational modifications rather than technical artifacts.

• Separation system considerations: Document the specific separation system used (e.g., "12-230 kDa separation system" as mentioned for Simple Western™) .

• Tissue-specific considerations: Recognize that UCP2 may display slightly different characteristics in different tissue sources due to tissue-specific post-translational modifications or protein interactions.

These approaches help ensure that molecular weight variations are properly interpreted in the context of the specific experimental system rather than incorrectly attributed to biological differences.

What strategies can optimize UCP2 antibody performance in challenging experimental contexts?

Optimizing UCP2 antibody performance in challenging experimental contexts requires targeted strategies:

• Sample preparation optimization:

  • For tissues with high lipid content (e.g., brown adipose tissue), use specialized extraction protocols to minimize lipid interference

  • Consider subcellular fractionation to enrich mitochondrial content when studying UCP2

• Signal enhancement approaches:

  • For low-abundance detection, consider tyramide signal amplification or other signal enhancement methods

  • Balance signal amplification with maintaining specificity

• Blocking optimization:

  • Test different blocking agents (BSA, non-fat milk, commercial blockers) to identify optimal conditions for reducing background without compromising specific signal

  • Consider specialized blocking for tissue-specific autofluorescence or endogenous peroxidase activity in IHC

• Antibody incubation conditions:

  • Optimize temperature, time, and antibody concentration through systematic titration

  • For Western blot, 1 μg/mL concentration of UCP2 antibody has proven effective

  • For Simple Western™, 10 μg/mL concentration was optimal

• Comparative antibody assessment:

  • Test multiple commercially available UCP2 antibodies in parallel

  • Document lot-to-lot variations that may affect performance

• Application-specific protocols:

  • Develop distinct optimization strategies for different applications (Western blot, IHC, flow cytometry)

  • Consider chemical crosslinking for stabilizing mitochondrial proteins during preparation

• Data acquisition optimization:

  • Adjust exposure times, gain settings, or PMT voltage to capture optimal signal range

  • Use appropriate software settings for quantification of signals with varying intensities

These strategies can significantly improve UCP2 antibody performance in technically challenging experimental contexts, enabling more reliable and reproducible research outcomes.

What are the future research directions for UCP2 antibodies in molecular and clinical research?

The emerging understanding of UCP2's roles in cellular function and disease suggests several promising future research directions:

• Development of conditional knockout models: Creating tissue-specific or inducible UCP2 knockout systems would enable more precise dissection of UCP2's roles in specific physiological contexts without developmental compensation .

• Therapeutic targeting validation: Development of antibodies that can functionally modulate UCP2 activity (rather than just detect it) could help validate UCP2 as a therapeutic target in conditions like anemia or cancer .

• Immune microenvironment research: Further investigation of UCP2's relationship with immune cell populations could elucidate its potential as an immunotherapy biomarker, particularly in Basal-like breast cancers that are more sensitive to immunotherapy .

• Single-cell analysis: Application of UCP2 antibodies in single-cell proteomics would allow for better understanding of UCP2 expression heterogeneity within tissues and its correlation with cellular phenotypes.

• Post-translational modification mapping: Development of modification-specific UCP2 antibodies could help understand how PTMs regulate UCP2 function in different contexts.

• Mitochondrial dynamics research: Investigating UCP2's role in mitochondrial morphology, fission/fusion, and quality control could reveal new aspects of its cellular functions.

• Clinical biomarker validation: Standardization of UCP2 IHC protocols for potential clinical application as a prognostic biomarker in breast cancer and potentially other malignancies .

These research directions would significantly advance our understanding of UCP2's biological functions and potential clinical applications, with UCP2 antibodies serving as critical tools in this endeavor.

How does UCP2 research contribute to broader understanding of mitochondrial biology in health and disease?

UCP2 research provides critical insights into mitochondrial biology with broad implications:

• ROS regulation mechanisms: UCP2's role in modulating ROS distribution between mitochondrial and cytosolic compartments advances our understanding of how cells manage oxidative stress . This has implications for aging research, neurodegeneration, and metabolic disorders.

• Metabolic flexibility: UCP2 contributes to our understanding of how mitochondria balance energy efficiency with cellular needs for signaling molecules and protection against oxidative damage.

• Cell fate determination: The involvement of UCP2 in erythropoiesis through MAPK/ERK signaling illustrates how mitochondrial proteins can influence cell proliferation and differentiation decisions , with broader implications for development and tissue homeostasis.

• Cancer metabolism: UCP2's association with cancer prognosis and immune cell infiltration highlights the interconnections between mitochondrial function, metabolism, and immune surveillance in the tumor microenvironment .

• Therapeutic targeting strategies: Research on UCP2 contributes to the growing arsenal of mitochondrial proteins that could serve as therapeutic targets, potentially enabling more precise interventions in mitochondrial function.

• Mitochondrial-nuclear communication: UCP2's effects on cytosolic ROS and subsequent impacts on nuclear signaling pathways like MAPK/ERK exemplify the importance of mitochondrial-nuclear communication in cellular homeostasis .

By deepening our understanding of these fundamental processes, UCP2 research contributes significantly to the broader field of mitochondrial biology and its implications for human health and disease.

What methodological advances would enhance UCP2 antibody research in the future?

Several methodological advances could significantly enhance UCP2 antibody research:

• Single-molecule imaging techniques: Development of super-resolution microscopy approaches specifically optimized for mitochondrial proteins would enable visualization of UCP2 localization and dynamics at unprecedented resolution.

• Proximity labeling technologies: Implementation of approaches like BioID or APEX2 fused to UCP2 would allow identification of proximal proteins, revealing UCP2's interactome in living cells.

• Conformational state-specific antibodies: Development of antibodies that recognize specific conformational states of UCP2 would provide insights into its functional status rather than just expression levels.

• Multiplex imaging platforms: Advanced multiplex IHC/IF techniques would enable simultaneous visualization of UCP2 with multiple markers of interest (e.g., immune cell markers, ROS indicators, signaling pathway components) .

• In situ protein-protein interaction detection: Methods like proximity ligation assay (PLA) optimized for mitochondrial proteins would allow visualization of UCP2 interactions in intact tissues.

• Automated image analysis algorithms: Development of machine learning approaches for quantifying UCP2 expression patterns in complex tissues would enhance reproducibility and throughput.

• Standardized antibody validation frameworks: Implementation of comprehensive validation standards specifically designed for mitochondrial proteins would improve reliability of UCP2 research.

• CRISPR-based endogenous tagging: Development of efficient methods for tagging endogenous UCP2 with reporter proteins would enable live-cell imaging of UCP2 dynamics without overexpression artifacts.